GHK-Cu Side Effects and Safety Profile: What the Research Actually Shows (2026)

# GHK-Cu Side Effects and Safety Profile: What the Research Actually Shows (2026)

For research purposes only. Not for human use. GHK-Cu is a research chemical and cosmetic ingredient. It is not an approved drug in any jurisdiction. This article reviews the published toxicology, copper chemistry and tolerability data so that researchers can design experiments and read supplier claims critically. It does not contain dosing or application instructions and is not medical advice.

The short version

There is no formal safety package for GHK-Cu in the peer-reviewed literature. What exists is a set of cell-culture and animal studies, one small randomized trial of a topical cosmetic after laser resurfacing, and decades of cosmetic use that has generated few published adverse-event reports. A 2026 scoping review in the American Journal of Sports Medicine that covered GHK-Cu alongside BPC-157 and TB-500 described "the absence of efficacy or safety data for many emerging peptides" and found that the few human studies were "most lacking robust controls or rigorous study designs" (Tewari et al., 2026).

The safety questions that the chemistry does raise are specific: how tightly the peptide holds its copper, what free copper does to cells, and whether a compound that stimulates fibroblast and keratinocyte activity should be used in models where proliferation is unwanted. Those questions have partial answers, covered below.

If you have read other pages that quote incidence figures for GHK-Cu skin irritation or hyperpigmentation (1–3%, "under 0.5%" and so on), treat them with suspicion. We could not trace any such figure to a published study, and this article does not repeat them.

What GHK-Cu is

GHK is the tripeptide glycyl-L-histidyl-L-lysine. It occurs in human plasma, saliva and urine, and plasma levels decline with age (Pickart et al., 2015). The sequence also appears inside the α2(I) chain of type I collagen, which led Maquart and Pickart to propose that proteases release it at wound sites (Maquart et al., 1988).

GHK binds Cu(II) spontaneously to form GHK-Cu, the blue-violet complex sold as "copper peptide." The copper is the point. GHK without copper has different, weaker activity in most assays, so a certificate of analysis for GHK-Cu should state copper content, not only peptide purity.

Copper chemistry: how tightly the peptide holds its metal

Free copper ions are toxic. Cu(II) and Cu(I) cycle through Fenton-type reactions that generate reactive oxygen species, and copper overload damages the liver, as in Wilson disease (Deloncle et al., 2025). At high concentrations copper triggers several regulated cell-death pathways, including a copper-specific one named cuproptosis (Xue et al., 2023). So the first safety question for any copper complex is how much copper it releases.

Isothermal titration calorimetry puts the conditional dissociation constant of GHK for Cu(II) at pH 7.4 at about 7 × 10⁻¹⁴ M, with 1:1 binding stoichiometry (Trapaidze et al., 2012). That is tight enough that, in a buffered solution without competing chelators, essentially all the copper stays bound to the peptide. It is not tight enough to survive EDTA, which binds Cu(II) several orders of magnitude more strongly. EDTA-containing buffers, cell-culture media supplements or dissociation reagents will strip the copper and turn the solution colourless. The same applies to strong reducing agents such as DTT, which reduce Cu(II) to Cu(I) and change the coordination chemistry.

GHK appears to reduce copper's redox activity rather than amplify it. In a 2024 study, GHK bound copper and lowered its redox activity, prevented copper- and zinc-induced death of central nervous system cells in vitro, prevented and reversed copper-induced albumin aggregation, and attenuated copper's enhancement of paraquat toxicity (Min et al., 2024). The authors framed GHK as a cytoprotective agent against copper toxicity, which is the opposite of the concern that a copper complex would add oxidative burden.

That finding covers GHK at the concentrations tested in vitro. It does not establish what happens when a model receives a large exogenous copper load over time, and no long-term systemic copper accumulation study of GHK-Cu exists in the indexed literature. A researcher using GHK-Cu in a hepatic model, or in any model of copper metabolism, should measure tissue copper rather than assume the complex is inert.

Cell-culture findings relevant to safety

Collagen stimulation without mitogenesis. In the original fibroblast study, GHK-Cu stimulated collagen synthesis from 10⁻¹² to 10⁻¹¹ M, with the maximum at 10⁻⁹ M, and the effect was "independent of any change in cell number" (Maquart et al., 1988). At those concentrations the peptide changed what fibroblasts made without changing how many there were.

Keratinocyte proliferation. Kang and colleagues found that copper-GHK increased keratinocyte proliferation in monolayer culture and increased PCNA and p63 positivity in skin-equivalent models, along with integrin α6 and β1 expression (Kang et al., 2009). p63 is a marker of basal keratinocyte stem and progenitor cells. For wound-healing research this is the desired effect. For a model that includes epithelial tumour cells, it is a reason for caution, because a compound that expands the basal proliferative compartment could confound tumour-growth readouts. No study has tested GHK-Cu in an epithelial cancer model to answer this either way.

Both synthesis and breakdown of matrix. GHK stimulates synthesis and breakdown of collagen and glycosaminoglycans and modulates both metalloproteinases and their tissue inhibitors (Pickart et al., 2015). This bidirectional effect is why "GHK-Cu builds collagen" is an oversimplification, and why matrix-remodeling readouts need MMP and TIMP measurements alongside hydroxyproline.

Aldehyde quenching. GHK reacts with 4-hydroxynonenal, a lipid-peroxidation product, at a rate comparable to carnosine (Beretta et al., 2007). This is one of the mechanisms proposed for its antioxidant effects, and it means GHK will consume reactive aldehydes in any assay where those are measured.

Animal data

Animal studies of GHK-Cu report efficacy endpoints far more often than toxicology endpoints. Two recent mouse studies are the exceptions worth reading.

In a silicosis model, GHK-Cu attenuated lung inflammation and fibrosis by binding peroxiredoxin 6 in alveolar macrophages, and the authors reported the effect occurred "without significant systemic toxicity" (Bian et al., 2024). A related study from the same field reported that GHK-Cu attenuated cigarette-smoke-induced emphysema in mice (Zhang et al., 2022). Neither is a toxicology study. The emphysema study gave GHK-Cu intraperitoneally to C57BL/6J mice over 12 weeks across a hundred-fold concentration range, which is the longest systemic exposure in the published record, and neither paper reported toxicity at the levels used.

Older wound-healing work in diabetic rats used a biotinylated GHK incorporated into collagen matrices and reported faster wound contraction and higher skin glutathione and ascorbate in treated animals, with no adverse findings noted (Arul et al., 2007). The 2015 Pickart review lists wound-healing effects in dogs, rats, mice and pigs (Pickart et al., 2015).

What is missing: no published LD50, no repeat-dose toxicology with organ histopathology, no genotoxicity battery and no reproductive toxicology for GHK-Cu as a research compound. The cosmetic industry's safety assessments for topical GHK-Cu are not, for the most part, in the peer-reviewed literature.

The one randomized human trial

Miller and colleagues randomized patients undergoing circumoral CO₂ laser resurfacing to post-treatment skin care with or without GHK-Cu. Thirteen patients completed the study. Blinded evaluators and computer image analysis found no statistically significant difference between groups in the resolution of erythema. Both groups improved in wrinkles and skin quality with no difference between them. The only difference was a patient questionnaire, on which the GHK-Cu group reported greater improvement in overall skin quality (p = 0.04) (Miller et al., 2006).

From a safety standpoint the study is reassuring in a narrow way: applying a GHK-Cu product to freshly laser-ablated skin did not slow erythema resolution or produce reported adverse effects. From an efficacy standpoint it found nothing on objective measures. With 13 patients it could not have detected an uncommon adverse event.

Pigmentation, irritation and the claims without sources

Two claims circulate widely on supplier pages and forums: that GHK-Cu causes hyperpigmentation through tyrosinase activation, and that it causes skin irritation at a specific low percentage of users. We searched PubMed for both. Neither is supported by a published study. Tyrosinase is a copper-dependent enzyme, so the mechanism is plausible on paper, but plausibility is not evidence. The honest statement is that GHK-Cu's effect on melanogenesis has not been established in the peer-reviewed literature, and that no published trial has measured irritation incidence.

The same goes for the reassuring claims. "No hormonal effects," "no cardiovascular effects" and "no effect on glucose" are all statements that no study has tested, not findings. A compound that has not been examined for an effect cannot be described as free of it.

Sourcing: what the Peptides.SO data shows

Peptides.SO tracks 108 suppliers with at least one GHK-Cu listing, across 75 distinct GHK or copper-peptide products (excluding palmitoyl-GHK and biotinyl-GHK, which are different molecules). The market divides into research-grade lyophilized vials, cosmetic raw materials and finished cosmetics. As of 13 September 2026:

Two products in our database are labelled "2:1," meaning two GHK molecules per copper. That is a legitimate cosmetic formulation, but it delivers half the copper per milligram of a 1:1 complex, and a CoA reporting "GHK-Cu purity" does not tell you which ratio you have. Two other listings are labelled "blue/purple colour" as a selling point. Colour confirms that copper is present and coordinated; it does not confirm the amount.

For research use, the questions to ask a supplier are:

1. Peptide purity by HPLC, with the chromatogram.

2. Identity by mass spectrometry, confirming the GHK mass (340.4 Da for the free peptide).

3. Copper content by ICP-MS or a validated colorimetric method, stated as a ratio or as percent by mass.

4. Endotoxin, if the material will go into cell culture or animals.

5. Whether the lot was tested by a third party. Our /compare tool flags suppliers that publish third-party certificates, and the CoA interpretation guide walks through reading one.

Handling in the lab

These points follow from the chemistry above and from general peptide-handling practice, covered in more depth in our research safety guide.

• •Keep GHK-Cu away from EDTA and other strong chelators unless stripping the copper is the intent.
• •Avoid DTT, TCEP and other reducing agents in the same solution.
• •Protect solutions from light and store lyophilized powder cold and dry, per the storage guide.
• •Treat the powder as a copper compound for waste purposes. Copper salts are regulated in aqueous waste in most jurisdictions.
• •Include copper-matched controls (for example, CuCl₂ at the same molar copper concentration) in any assay where copper alone could produce the effect.

FAQ

Is GHK-Cu toxic?

No published LD50 or repeat-dose toxicology study exists. In cell culture, GHK reduces copper's redox activity and protects cells from copper- and zinc-induced death rather than adding to it. Two mouse studies that gave GHK-Cu systemically reported no significant systemic toxicity. None of that amounts to a safety package.

Does the copper accumulate?

Unknown. No study has measured tissue copper after repeated GHK-Cu exposure. The binding constant (about 7 × 10⁻¹⁴ M) means very little copper is free in solution, but bound copper still enters an organism and has to be handled by the same pathways as dietary copper.

Why is it blue?

The colour is the Cu(II) ion coordinated by the histidine imidazole nitrogen, the terminal amine and backbone amide nitrogens of the peptide. A colourless GHK-Cu solution has lost its copper, usually to a chelator.

Is GHK without copper the same thing?

No. Copper-free GHK has been studied separately and has some activity, but the collagen-synthesis, keratinocyte and wound-healing results above were obtained with the copper complex. Suppliers sometimes sell copper-free GHK under the same name.

Does GHK-Cu cause hyperpigmentation?

Not established. No peer-reviewed study has tested GHK-Cu's effect on melanogenesis. The claim rests on the fact that tyrosinase is a copper enzyme, which is a hypothesis.

Are there human safety trials?

One small randomized trial (13 patients) of a topical GHK-Cu product after laser resurfacing found no difference in erythema resolution and reported no adverse effects. There are no human trials of injected GHK-Cu in the peer-reviewed literature.

What about GHK-Cu in a stack with BPC-157 and TB-500?

No study has tested the three together. Our recovery stack article covers what has been tested, including a 2026 rat study in which BPC-157 plus TB-500 did no better than either alone.

Related reading

• •GHK-Cu research profile
• •GHK-Cu vs BPC-157
• •Peptide purity testing: HPLC and mass spec
• •Research peptide regulatory landscape

References

1. Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. PMID 42578445

2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730

3. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PMID 3169264

4. Deloncle R, Guillard O, Pineau A. Copper in human health: From COVID 19 to neurodegenerative diseases. J Trace Elem Med Biol. 2025;89:127636. PMID 40184864

5. Xue Q, Kang R, Klionsky DJ, et al. Copper metabolism in cell death and autophagy. Autophagy. 2023;19(8):2175-2195. PMID 37055935

6. Trapaidze A, Hureau C, Bal W, et al. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID 21898044

7. Min JH, Sarlus H, Harris RA. Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Metallomics. 2024;16(5):mfae019. PMID 38599632

8. Kang YA, Choi HR, Na JI, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-6. PMID 19319546

9. Beretta G, Artali R, Regazzoni L, et al. Glycyl-histidyl-lysine (GHK) is a quencher of alpha,beta-4-hydroxy-trans-2-nonenal: a comparison with carnosine. Chem Res Toxicol. 2007. PMID 17672515

10. Bian Y, Deng M, Liu J, et al. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024;75:103237. PMID 38879894

11. Zhang Q, Yan L, Lu J, et al. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. PMID 35936787

12. Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 2007;80(4):275-84. PMID 17049946

13. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PMID 16847171

---

For research purposes only. Not for human use. Peptides.SO does not sell peptides and does not provide medical advice. Supplier data reflect our database snapshot on the date stated.